Tivic Health winds down ClearUP consumer biz; Q3 net loss $2.6M

Valion Bio, Inc.

Q3 revenue $146K (+16% YoY); gross loss $145K from $230K inventory reserve for ClearUP exit.
Net loss $2.6M vs $1.4M in Q3 2024; operating expenses rose to $2.3M on biopharma costs.
ClearUP wind down: $347K charge incurred, $20-50K more expected; minimal revenue until approval.
Transferred two INDs for Entolimod (neutropenia, cancer); cell line verification for cGMP completed.
Cash $3.5M; $3.5M available via preferred equity; no debt.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.